Inherited Forms of Bladder Cancer: A review of Lynch Syndrome and Other Inherited Conditions by Phelan, Aaron et al.
Inherited Forms of Bladder Cancer: A review of Lynch Syndrome and Other Inherited 
Conditions 
Aaron Phelan, MD1, Antonio Lopez-Beltran, MD2, Rodolfo Montironi, MD3, Shaobo Zhang, 
MD1, Maria R. Raspollini, MD4, Hristos Z. Kaimakliotis, MD5, Michael O. Koch, MD5, Liang 
Cheng, MD1,5
From Departments of Pathology1 and Pathology5, Indiana University School of Medicine, 
Indianapolis, USA; 2Unit of Anatomical Pathology, Faculty of Medicine, Cordoba, Spain and 
Champalimaud Clinical Center, Lisbon, Portugal; 3Institute of Pathological Anatomy and 
Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), 
United Hospitals, Ancona, Italy; 5Histopathology and Molecular Diagnostics. University 
Hospital Careggi, Florence, Italy. 
Running Head: Bladder Cancer: Familial Variants and Heritability 
Key words: Bladder, Lynch Syndrome, Urothelial Carcinoma, Molecular Genetics, 
Microsatellite instability (MSI), Screening   
Total number of text pages, 18; Number of tables, 3; Number of figures, 2 
Conflict of interest: None 
Address correspondence and reprint requests to Liang Cheng, M.D., Department of Pathology 
and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, IUHPL 
Room 4010, Indianapolis, IN 46202, USA. Telephone: 317-491-6442; Fax: 317-491-6419;  
E-mail: liang_cheng@yahoo.com
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Phelan, A., Lopez-Beltran, A., Montironi, R., Zhang, S., Raspollini, M. R., Cheng, M., … Cheng, L. (2018). Inherited 
forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. Future Oncology, 14(3), 277–290. 
https://doi.org/10.2217/fon-2017-0346
2 
 
Abstract 
Environmental factors that play a role in the pathogenesis of bladder cancer have been 
characterized for many years.  Current research into the pathophysiology of bladder cancers has 
begun to focus more on genetic alterations that are important in tumorigenesis.  Low penetrance 
polymorphisms, such as N-acetyl transferase 2, glutathione S-transferase, and others have also 
shown to increase the risk of bladder cancer by altering the processing of environmental toxins.  
Additionally, Lynch syndrome is a well-known inheritable disease that increases the risk for a 
variety of cancers, including urothelial carcinomas.  The development of bladder cancer is still 
not as well understood in Lynch syndrome as other classical Lynch syndrome associated cancers, 
such as colorectal and endometrial cancer.  Research is continuously exploring potential 
heritable forms of bladder cancer.  Screening of patients with known Lynch syndrome is also 
important to evaluate for development of new primary tumors.  The focus of this article is to 
review the current available literature on familial bladder cancer variants, as well as to provide a 
review of Lynch syndrome and its association with urothelial tumors. 
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1. Introduction 
In 2017, it is estimated that bladder cancer will compose 5% of all new cancer diagnoses 
at around 79,030 new cases[1].  Additionally, an anticipated 16,870 deaths (3% of all projected 
cancer deaths) will be due to bladder cancer[1]. A number of factors have been identified that 
contribute to the development of bladder cancer.  Environmental factors, such as cigarette 
smoking and exposure to aromatic amines have been identified as the major contributors to 
increased bladder cancer risk [2-4].  However, the genetic and inheritable components of bladder 
cancer remain more of a mystery.  Identification of Mendelian inheritance patterns in bladder 
cancer has been difficult due to a limited number of familial cases to explore [5].  New case 
reports and case studies have slowly become available, as well as follow up on families with 
multiple effected members.  Large case studies are also limited with few new studies available.  
The most information regarding the heritability of bladder cancers seems to arise from the new 
research into Lynch syndrome and low penetrance polymorphisms [6-8].   
The association of Lynch syndrome with urothelial cancers is relatively new.  Urothelial 
cancers were only recently included in the criteria that assist in the diagnosis of Lynch 
syndrome[8].  The malignancies classically associated with Lynch syndrome are colorectal 
cancer and, to a degree, endometrial cancer[9-14].  These tumors have seen much more extensive 
study in their relation to Lynch syndrome than urothelial and other cancers.  Moreover, while the 
association between Lynch syndrome and upper tract urothelial cancers is apparent, the direct 
relationship between Lynch syndrome and bladder cancers is less well understood.  Increases in 
bladder cancer in patients with Lynch syndrome may be the result of downstream seeding from 
primary upper tract cancers, and may not represent primary bladder cancers[8].  More research is 
necessary in this area to truly delineate the relationship. 
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In addition to Lynch syndrome, research is also active regarding low penetrance 
polymorphisms and their relation to bladder cancer. The most prolific polymorphisms include N-
acetyl transferase and glutathione S-transferase.  The presence of these polymorphisms only 
slightly increases the individual risk of bladder cancer, but they are prevalent in certain 
populations.  The role these polymorphisms play in familial clustering of bladder cancers is still 
poorly understood.  However, multiple polymorphisms coupled with consistent environmental 
exposure may explain families with multiple generations affected by bladder cancer[7]. 
 
2. Case based evidence for inherited variants of bladder cancer 
The first case study to mention a familial linked bladder cancer was published in the late 
1950's.  In this paper, Thelen and Schaebule presented monozygotic twins with transitional cell 
papillomas of the bladder[15].  Since that time, several additional case studies have presented 
families with multiple members affected by bladder cancers.  A paper published in 1967 by 
Fraumeni and Thomas reported a father and three of his sons with bladder transitional cell 
carcinoma[16].  Blattner et al. published follow up for this family in 1983 with additional follow 
up by Mueller et al. in 2008[7, 17].  At that time, the niece of the proband had also been 
diagnosed with bladder cancer.  All affected family members reported an extensive smoking 
history, but had no other identifiable environmental risk factors.  Studies for the more common 
variable penetrance polymorphisms were also performed, but all affected family members were 
negative for the genes associated with higher bladder cancer risk.   
Mcullough et al. also reported a family with six affected family members in only two 
generations.  This family also had numerous other cancers[18].  In their paper from 2008, 
Mueller et al. also summarized 16 case studies involving 32 families with transitional cell 
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carcinoma.  Important factors to note in these cases are exposures to known environmental risk 
factors, mainly smoking and occupation exposure to aromatic amines.  For 40 of the 86 affected 
individuals, smoking history was unavailable.  In the remaining 46 patients, 33 had a positive 
smoking history.   In this conglomerate of cases, smoking history was reported in at least one 
family member in all of the cases[7].  A more concise version of the table presented in that 
article is shown in Table 1[7, 16-28], with the addition of some more recent case studies.   
Studies of more recent cases on familial clustering of bladder cancers include Ilic et al., 
where they describe a mother and son with bladder transitional cell carcinoma[27].  In addition, 
Brown et al. introduced two families with three cases of bladder transitional cell carcinoma 
each[28]. 
Deciphering the underlying predisposing factors in these families remains a challenge.  
Some patients had clear risk factors with smoking histories or occupational exposure to 
carcinogens.  Others have no discernable risk factors, even when tested for cancer-predisposing 
polymorphisms.  The paucity of available cases in this regard limits the information that can be 
ascertained from these case studies.  Ultimately, more cases with are required to reach a more 
definitive conclusion.   
 
3. Population based evidence for inherited variants of bladder cancer 
Kramer et al. conducted a cross-sectional study in 1991 on 319 men with bladder cancer 
and another 319 neighborhood controls.  In this study, an investigation was made into the 
relatives of the selected participants.  The study looked at 1619 relatives of the men with bladder 
cancer and identified 14 family members with bladder cancer.  Only seven effected family 
members were identified out of the 1773 members of the control group[29].  Kiemeney et al. 
6 
 
reviewed the families of 190 bladder cancer patients in Iceland and found family members with 
urinary tract transitional cell carcinoma in 41 of the families.  Of interest in this study is that 2nd 
and 3rd degree relatives were more commonly affected[30].  A large case-control study in the 
Netherlands looked at 8014 family members of patients with transitional cell carcinoma and 
5673 control relatives.  One hundred and one relatives with urinary tract cancers were found in 
the family members of patients with urinary tract transitional cell carcinoma, whereas only 38 
family members were affected among controls[31].  A study from Spain of 1158 cases reported 
increased risk for developing bladder cancer in those with a positive family history.  This was 
stronger among slow acetylators, but not to a degree that was statistically significant[32].  
Goldgar et al. also looked at Utah databases to prove increased risk of cancer in family members 
of cancer patients.  This risk was much greater when younger probands were viewed[33].  A twin 
study from Denmark, Sweden and Finland from Lichtenstein et al reported three to four fold 
higher relative risk of bladder cancer among monozygotic twins than among dizygotic twins[34].  
Another twin study from 2016 studied the increased cancer risk for monozygotic and dizygotic 
twins in Nordic countries.  This study showed a 2.2% cumulative increase in the risk of bladder 
and other urinary organs for patients who had a mono or dizygotic twin with urinary tract 
cancer[5]. Dong and Hemminki used the Swedish Family-Cancer Database for more than 5 
million offspring.  The risk was increased by 1.5 with one affected parent and 3.3 also with an 
effected sibling[35]. 
 
4. Bladder cancer susceptibility genes 
Some of the most well known risk factors for bladder cancer are environmental toxins.  
Cigarette smoke and occupational exposure to aromatic amines have been well studied and their 
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contribution is clear[2].  Less well understood, however, is how genetic differences between 
individuals and their ability to process these toxins effect the development of bladder cancer.  
Environmental toxins are processed by a number of different enzymes. Many polymorphisms 
have been identified that may increase the risk for developing bladder cancer[7]. 
  N-acetyl transferase 2 is one of the most prominent polymorphisms in the literature.  
This polymorphism is extremely prevalent, found in approximately 50% of Caucasians.  The 
odds ratio of the development of bladder cancer in patients with this polymorphism is 1.4 (95% 
CI 1.2–1.6)[7].  The protein product of this gene is responsible for detoxifying amines.  A patient 
with the slow acetylator phenotype would therefore have a greater risk from exposure to 
environmental amines, either from cigarettes or occupational exposures.  This longer exposure 
time increases the risk of bladder cancer.  The fast acetylators would more quickly clear the 
toxins and would not be at as great of risk.  Although some authors show evidence supporting 
this association, there is still contention as to whether there is sufficient statistical power to prove 
this relationship[36].   
Another genetic polymorphism of interest is glutathione S-transferase. This family of 
enzymes, belonging to the mammalian glutathione transferase family, is responsible for 
catalyzing conjugation of electrophilic substrates with glutathione.  This conjugation results in 
detoxification of certain chemicals.  The glutathione S-transferase M1 gene in particular 
detoxifies polycyclic aromatic hydrocarbons, many of which have been identified as 
carcinogenic.  Glutathione S-transferase M1 is important in cancer prevention, thus a deficiency 
in this gene or protein product results in susceptibility to malignancy.  Lack of this gene and 
product can be found in those patients who have inherited two copies of the null gene.  Those 
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with the null phenotype for this gene find themselves at greater risk for developing bladder 
cancer[7, 37].   
Some studies have estimated that 31% of bladder cancer in Caucasians may be due to 
deficiency of glutathione S-transferase or N-acetyl transferase 2.  Additionally, many other gene 
variations have been studied and proposed as increasing the risk of familial bladder cancer[37].  
These genes require more study, but give us more insight into the development of bladder 
cancer. 
 
5. Lynch Syndrome 
5.1 Epidemiology 
 Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer is the most 
common cause of hereditary colorectal and endometrial cancers, accounting for approximately 1-
3% of all colorectal cancers and 2-5% of all endometrial cancers[8].  Lynch syndrome is 
classically associated with increased risk of colorectal cancer, but also increases the risk of 
several other cancers (Table 2)[8, 38, 39].  In women, endometrial cancer may actually be the 
sentinel malignancy[11].  A subset of Lynch syndrome, Muir-Torre syndrome, can also result in 
skin and sebaceous gland malignancies[40].  Lynch syndrome patients are additionally at 
increased risk for ovarian, urinary tract, stomach, small bowel, hepatobiliary, and central nervous 
system neoplasms[8].  The association of Lynch syndrome with these neoplasms is still growing 
due to limitations of early studies of Lynch syndrome, including small sample size, lack of 
disease confirmation, and limited or no availability of genetic testing.  There is also equivocal 
evidence that malignancies of the prostate, testis, kidney, and adrenal gland may be slightly 
increased in Lynch syndrome patients.  The susceptibility in Lynch syndrome to these particular 
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neoplasms is not as frequently reported and they may develop through pathways other than 
MSI[8]. 
The risk of urothelial tract cancer in Lynch syndrome has been reported to increase by up 
to 28%[8, 41].  Research shows these urothelial tract cancers to include renal pelvis and ureter 
tumors (Figure 1).  Bladder cancers noted in cases of Lynch syndrome could be due to 
implantation of tumor cells from upstream into the bladder mucosa.  The true risk may be even 
higher, with some urothelial cancers suspected to be misclassified as sporadic[8]. 
 Research has shown that sporadic colorectal cancers have different characteristics than 
colorectal cancers associated with Lynch syndrome[8].  Lynch syndrome associated cancers 
present at a younger mean age, which are usually right sided, and more likely multifocal.  
Additionally, colon polyps in Lynch syndrome patients develop at a younger age, are smaller, 
and are more likely to be villous polyps.  Differences between sporadic and Lynch syndrome 
associated urothelial cancers are also seen with Lynch syndrome patients more likely to develop 
urothelial cancers at a younger age (an average of 8 years younger according to one study), 
though one study showed no association with early bladder cancers and MSI.  Additionally, there 
appears to be a slight female predominance and some studies suggest higher incidence of 
bilateral involvement of the upper urothelial tract[8].  One study suggested an association 
between inverted growth pattern and MSI and Lynch syndrome[42].   
Prognosis and response to treatment also varies in sporadic versus Lynch syndrome 
associated colorectal cancers, and it has been postulated that the same may be true for urothelial 
cancers.  Patients with Lynch syndrome associated colorectal cancers appear to have superior 
overall survival[8].  More research is still required to evaluate the differences between sporadic 
and Lynch syndrome associated urothelial cancers. 
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5.2 Genetics 
Lynch syndrome is an autosomal dominant genetic disease caused by mutations in 
mismatch repair (MMR) genes.  Four mismatch repair genes can be mutated in Lynch syndrome, 
and a mutation in one of these genes predisposes to several different malignancies.  The four 
MMR genes are MLH1, MSH2 (and its modifier EPCAM), MSH6, and PMS2.  Mutations in 
these genes lead to accumulation of DNA errors in microsatellite regions of the genome.  This 
phenomenon is also known as microsatellite instability (MSI).  Microsatellites are short, non-
coding, and repeating sequences of DNA.  Instability in these regions as the result of shortening 
or lengthening of these repeating sequences can lead to malignant transformation of effected 
cells.  The MMR deficiencies in Lynch syndrome lead to lengthening of these sequences, a.k.a., 
MSI-high tumors.  The importance of MSI low tumors is not as well understood.  Some sporadic 
tumors may also possess MSI high sequences, and this should also be taken into consideration 
when assessing for Lynch syndrome[8, 14].   
Additionally, a mutation in the MSH2 gene seems to confer a higher risk for urothelial 
cancer than mutations in the other MMR genes.  The increase in urothelial cancers is 
predominantly within the renal pelvis and ureters.  Some studies have shown an increased risk 
for bladder cancer as well, but this increased risk may be due to seeding of the bladder from 
primary tumors that are upstream[8]. 
 
5.3 Diagnosis 
When thinking of Lynch syndrome, clinicians classically associate this disease with GI 
malignances, thus a disease specific to gastroenterologists. However, urologists also need to be 
aware of Lynch syndrome when patients present with primary bladder cancers.  Urologists play 
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important roles in identifying, screening, and treating patients with Lynch syndrome.  Clinical 
criteria, tumor tissue testing, and genetic germline testing are all available to assist in the 
diagnosis of Lynch syndrome.  Upper urinary tract cancers are considered a core malignancy of 
Lynch syndrome and are included in both the revised Bethesda Guidelines and the Amsterdam II 
criterion [8]. 
The initial Bethesda Guidelines were developed in 1996, when an international workshop 
was hosted by the National Cancer Institute to further the clinical and histological manifestations 
of Lynch syndrome and MSI testing.  These guidelines were revised at a similar workshop in 
2002.  The revised Bethesda Guidelines works to identify those patients in which Lynch 
syndrome testing is warranted in order to aid providers in appropriate patient care.  The revised 
Bethesda Guidelines provide five scenarios in which Lynch syndrome testing should be pursued.  
The first scenario suggests testing in patients who present with colorectal cancer and are less 
than 50 years old.  Patients with synchronous or metasynchronous Lynch syndrome associated 
tumors should be tested regardless of age.  Those patients with colon cancer who have a high 
MSI histology (defined as tumor infiltrating lymphocytes, Crohn’s like lymphocytic reaction, 
mucinous/signet ring differentiation, or medullary growth pattern) who are less than 60 years old 
should also be tested.  A family history of colorectal cancer and another Lynch syndrome 
associated cancer diagnosed in at least one first-degree relative also indicates the need for 
testing.  The final Bethesda Guideline recommends testing in the instance of two first or second-
degree relatives with colorectal cancer and a second Lynch syndrome associated tumor, 
regardless of their age [43].   
Initial identification of Lynch syndrome in patients who present with urothelial cancers is 
similar to algorithms used with colorectal cancers[8].  Screening for patients with colon cancer 
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usually takes the form of MSI testing in patients with colorectal cancer who are younger than 50 
years old.  This form of testing is generally cost effective while also detecting most of the 
patients with Lynch syndrome.  Prediction models can also be helpful[13, 14, 43].   
Testing for MSI in urothelial tumors should be focused on those patients for whom there 
is high clinical suspicion (Figure 2).   The clinical history is paramount in identifying those 
patients who would benefit most from testing.  An extensive family pedigree is a major aid and 
should be collected on all patients.  The Bethesda Guidelines and the Amsterdam II criterion are 
a useful tool for clinicians.  The Amsterdam II criteria, however, are somewhat strict and may 
fail to identify some patients with Lynch syndrome.  The sensitivity of the criteria have been 
reported to be approximately 72%, and studies using more broad criteria for testing have been 
able to identify additional Lynch syndrome patients that were missed on screening with the 
Amsterdam II criteria.  Some international guidelines use upper tract urothelial cancer and age 
less than 60 as a trigger for genetic testing[8, 43]. 
Patients who present at a young age (<60 years), with a family history of urothelial, 
colorectal, or endometrial cancers, or those patients who have a personal history of colorectal or 
endometrial cancer should have malignant tissue tested for MSI.  Initial testing should be 
performed with immunohistochemistry or PCR testing.  The national cancer institute has 
suggested a 5-marker panel including five different alleles for MSI testing.  A shift in 30% or 
more of these alleles is necessary for the tissue to be designated as MSI high.  PCR testing may 
be necessary as 10% of MMR mutated tumors may not have loss of proteins on 
immunohistochemical testing[8, 43].   
Immunohistochemical testing of tissue uses protein specific antibodies to highlight the 
loss of the MMR proteins by staining the products of the MLH1, MSH2, MSH6, and PMS2.  For 
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MSI high tumors or tumors with protein loss, germline genetic testing should be considered.  In 
cases where the immunohistochemistry has revealed loss of a specific protein, the focus of the 
testing can be targeted at the specific gene.  If tumor tissue cannot be adequately tested in a 
family where suspicion for Lynch syndrome is high, comprehensive germline genetic testing of 
the MMR genes can also be performed.  Existing prediction models can assist in these cases 
where tumor testing is unavailable.  Loss of MLH1 and PMS2 on IHC can also be due to BRAF 
V600E mutation and MLH1 hyper methylation, and these should be ruled out in colorectal tumor 
samples before pursuing genetic testing.  It is important to keep in mind with regard to MMR 
testing that the testing has been validated for colorectal and endometrial tumor specimen.  
Therefore, negative studies in other tissue types may not necessarily exclude the possibility of 
Lynch syndrome[8, 14, 43]. 
 
5.4 Screening for urothelial cancers in patients with diagnosed Lynch syndrome 
 Patients with Lynch syndrome require a number of distinct considerations in regard to 
screening for Lynch syndrome associated cancers.  Colonoscopies in these patients should be 
performed earlier and more frequently.  The appropriate frequency and age of first colonoscopy 
can vary depending on particular gene effected within the family, as well as the age of first 
colorectal cancer diagnosis in the family[14].  Additionally, female Lynch syndrome patients 
should be advised to consider early hysterectomy to prevent endometrial cancers[11].   
Patients with diagnosed Lynch syndrome require special consideration for early 
identification of urothelial tract cancers.  There is still no widely agreed upon method for 
screening these patients.  Urinalysis and urine cytology remain the default screening method for 
patients with Lynch syndrome.  These methods are fairly cheap and noninvasive which make 
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them an easy to perform screening test.  Urine cytology, however, has a low sensitivity of 
approximately 29%, despite its high specificity for high grade lesions.  This means that many 
patients with low-grade urinary tract cancers can easily be overlooked with this testing.  
Therefore, urine cytology should not be used alone for screening Lynch syndrome patients for 
urothelial cancers.  Other suggested methods have included renal ultrasound, urine dipstick, and 
NMP-22 testing.  Patients with a previously diagnosed urothelial tract cancer or the MSH-2 
mutation are considered to be at higher risk of tumor formation and vigilance in these patients is 
prudent[8]. 
 Hematuria identified on urinalysis can be a concerning feature and should be investigated 
further.  Gross hematuria requires the default urological evaluation, including cystoscopy and 
biopsy.  Microhematuria as a tool has low sensitivity for the evaluation of recurrent upper tract 
cancers, with a sensitivity of approximately 37.5%.  Microhematuria is also relatively common 
in the general population, with no history of urothelial cancers[8].  One study revealed 41% of 
the general population to have a urinalysis with microhematuria[44].  Microhematuria should 
trigger further evaluation with greater than 3 red blood cells per high power field.   
 Routine imaging studies in patients with Lynch syndrome are common, but also pose risk 
with increased radiation exposure.  Patients with a previously diagnosed malignancy can expect 
yearly CT imaging.  Patients at higher risk, those with previous upper urothelial tract cancers or 
PMS2 mutations, may benefit from routine CT urograms[8]. 
 More definitive methods for identifying early urothelial tract tumors are not without their 
risks.  Cystoscopy is minimally invasive, visualization of the ureters and renal pelvis requires 
more risk to the patient.  This may include radiation exposure and exposure to anaesthetic[45].     
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The association of Lynch syndrome with urothelial cancers is not as old as the association 
with colorectal and other cancers.  It was not until the Amsterdam Criteria II revision in 1999 
(Table 3)[34] that non-colonic Lynch syndrome cancers began to be truly appreciated.  
Therefore, more research is required to hone our knowledge regarding urothelial cancers and 
Lynch syndrome [8]. 
Patients with Lynch syndrome have increased risk of bladder cancer. The 
recommendations of Mork et. al. in their 2015 article on Lynch syndrome and urothelial cancers 
are frequent screens for hematuria on urinalysis, with a threshold of 3 RBC/HPF.  Additionally, 
for patients with previous Lynch syndrome malignancies, CT urogram or MR urogram can be 
performed to assess for upper tract malignancies[8].       
 
6. Conclusions 
The medical literature to this point does not provide irrefutable evidence for a true 
Mendelian pattern bladder cancer.  Since the first case report by Thelen and Schaebule, many 
more cases have been reported which portray many families with multiple members affected by 
bladder cancer.  Additional risk factors are present within many of these families, making it more 
difficult to elucidate the true role of inheritance.  With these environmental exposures in 
common to explain the familial clustering, a true Mendelian cause becomes less likely.  
Population based studies using large patient databases have also given us some information.  All 
of these studies have revealed that relatives of patients with bladder cancer are more likely to 
develop bladder cancer themselves when compared to the general population.  Part of this 
increased risk could be attributed to shared environmental factors, as in some of the individual 
case studies.   Close relatives are likely to share important history characteristics, such as 
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smoking and occupational exposures to aromatic amines.  In addition, the case literature is 
limited in that most of these cases follow only a couple of generations.  Few multigenerational 
cases have been reported.  Not all of these population based studies may have the important 
historical data available, but even so, it seems unlikely that all of the familial clustering can be 
attributed to environmental risk factors.  This is where the genetic polymorphisms may play a 
role.  Many polymorphisms have come to light that seem to increase the risk of bladder cancer.  
The NAT2 and glutathione transferase genes seem to be some of the more well studied genes, 
but many more have been characterized as increasing the risk of bladder cancer.  Even more so, 
other cancer predisposition syndromes such as Lynch syndrome have shown that they can lead to 
increased incidence of bladder cancer.  These add an additional level of difficulty when trying to 
evaluate families for potential Mendelian patterns of inheritance.  At this point, more study is 
required to more clearly elucidate the myriad factors involved in the development of bladder 
cancer. 
Lynch syndrome is one important factor to consider in inherited urothelial tumors.  
Though these types of tumors are less well studied in Lynch syndrome, the current research 
clearly shows the increased risk of urothelial tumors in this syndrome.  Screening of patients 
with known Lynch syndrome is also important to evaluate for development of new primary 
tumors.   
 
7. Future Perspective 
The coming years will undoubtedly bring us a greater understanding of the genetics of 
bladder cancer.  Study into these genetic alterations is becoming a topic of increasing interest 
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with many new polymorphisms being identified, as well as our understanding of urothelial 
cancers in Lynch syndrome being refined.   
Much can be expected to surface about the association of Lynch syndrome and its role in 
urothelial cancers.  Bladder, ureter, and renal pelvis cancers remained an underappreciated 
portion of the syndrome until the last couple of decades.  This recognition has allowed an 
increasing number studies to shine light on these associations.  In the future we will likely see 
further and more expansive studies to refine our understanding.  The real association of Lynch 
syndrome and bladder cancer is still poorly understood, for example.  We currently do not fully 
understand the actual risk of bladder cancer in Lynch syndrome.  Increases in incidence may 
simply be due to downstream seeding from upper tract cancers.  Further studies will no doubt 
illuminate this problem and provide us with more concrete answers. 
Next generation sequencing is only just starting to blossom.  Sequencing at this point is 
still expensive and the sequencing of multiple patients for study may not be practical in all cases.  
As with most advances, the cost of next generation sequencing will likely decline rapidly over 
the coming years.  As this process is made more efficient and cost effective we will see increased 
application in large scale studies in many areas, including bladder cancer and urothelial cancer 
research.  Large scale application of this process will lead to the discovery of many additional 
genes in carcinogenesis in addition to improving our understanding in epidemiology for currently 
poorly understood alterations, such as many of the single nucleotide polymorphisms, which have 
limited evidence. 
Additionally, screening for patients with Lynch syndrome may see changes in the coming 
years.  Currently proposed screening methods involve measuring hematuria and the use of urine 
cytology with some providers using more costly and invasive measures such as cystoscopy or CT 
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and MRI.  Further study may provide more information on what level of follow-up each patient 
needs.  We can already see that some mismatch repair mutations confer a greater risk for 
urothelial cancer.  Additional large patient series as well as advancement of molecular testing 
may provide triage for Lynch syndrome patients in regards to the frequency and type of 
screening best suited for each patient. 
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Executive Summary 
 
Case Based Evidence for Inherited Variants of Bladder Cancer 
 Familial clustering of bladder cancer that cannot be attributed to known genetic 
predispositions has been observed in multiple case studies. 
 Many of the effected family members in these case studies do share some environmental 
predispositions such as smoking and occupational exposures. 
 The evidence is suggestive of additional genetic predispositions to bladder cancer, but no 
definitive conclusions can be made and further research is required. 
Population based evidence for inherited variants of bladder cancer 
 Patients with bladder cancer are more likely than the general population to have relatives 
who also have a history of bladder cancer. 
Bladder cancer susceptibility genes 
 N-acetyl transferase 2 polymorphism has been shown in some studies to increase the risk 
of bladder cancer. 
 N-acetyl transferase 2 is found in approximately 50% of the Caucasian population. 
 The slow acetylator phenotype for N-acetyl transferase 2 results in longer exposure times 
to environmental factors proven to cause bladder cancer. 
 Glutathione S-transferase M1 is responsible for detoxifying polycyclic aromatic 
hydrocarbons. 
 Inheritance of two null copies of the Glutathione S-transferase M1 gene result in a higher 
risk of bladder cancer. 
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Lynch syndrome 
 The risk of urothelial tract cancer in Lynch syndrome has been reported to increase by up 
to 28%. 
 Urothelial cancers in Lynch syndrome have been shown by some studies to be diagnosed 
at younger ages and have a slight female predominance. 
 Lynch syndrome is caused by mutations in one of the mismatch repair genes: MLH1, 
MSH2, MSH6, and PMS2 
 Mutations in MSH2 have been shown to confer higher incidence of urothelial cancer in 
Lynch syndrome. 
 History coupled with the Amsterdam II or revised Bethesda criteria can be used to triage 
IHC, PCR, and germline genetic testing in patients with urothelial cancers. 
 Hematuria with a threshold of 3 rbc/hpf can be used for urothelial cancer screening in 
patients with Lynch syndrome. 
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Figure Legends 
Figure 1.  Morphology of urothelial carcinoma in a Lynch syndrome patient 
 The figure shows representative histologic images of a 78-year-old female Lynch syndrome 
patient with high-grade papillary urothelial cell carcinoma in a ureter.  A. Low power view of a 
cross section of ureter filled with tumor.  B. Low power view showing tumor papillary 
architecture.  C. High power view showing high-grade full thickness atypia of the urothelium.  
D.  High power view showing nuclear pleomorphism. 
 
Figure 2. Algorithm for MSI testing in urothelial cancers.  The identification of Lynch 
syndrome begins with clinical suspicion based upon family history, patient history, and pedigree 
as outlined in the Bethesda guidelines and the Amsterdam II criteria.  MSI testing by IHC can be 
performed alone, or in conjunction with PCR methods (IHC alone may miss a subset of Lynch 
cases).  Loss of protein expression on IHC, or detection of MSI-high alterations on PCR warrant 
further testing, including genetic counselor consultation and germline genetic testing. UUTC: 
upper urinary tract cancer.  
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Table 1.  Familial Bladder Cancer Case Studies 
 
Author Year of 
Study 
Relation to 
proband 
Sex Age Environmental 
Risk Factors 
Fraumeni[16] 
Blattner[17] 
Mueller[7] 
1967 
1983 
2008 
Proband Male 58 Smoking 
Sibling Male 59 Smoking 
Sibling Female 70 Smoking 
Paternal 
Cousin 
Female 66 Smoking 
Father Male 54 Smoking 
Benton[19] 1973 Proband Male 19 Machinist 
Father Male Unknown Welder 
Mcullough[18] 1975 Proband Male 36 Smoking 
Sibling Male 35 Smoking 
Printer 
Father Male 44 Smoking 
Painter 
Paternal 
Uncle 
Male 65 Mechanic 
Paternal 
cousin 
Female 48 Lived on a farm 
Paternal 
Uncle 
Male 60 Smoking 
Farmer 
Leklem[20] 1976 Proband Female 65 Smoking 
Art teacher 
Sibling Male 51 Smoking 
Petroleum plant 
Sharma[21] 1976 Proband Male 83 Smoking 
Child Male 58 None known 
Purtilo[22] 1979 Proband Male 62 Smoking 
Textile dye 
Sibling Male 55 Smoking 
Machinist 
Proband Male 59 Smoking 
Textile dye 
Sibling Male 56 Smoking 
Leather 
Proband Male 91 None known 
Sibling Female 89 None known 
Proband Male 39 Smoking 
Machinist 
Sibling Male 52 None known 
Proband Male 33 Smoking 
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Bricklayer 
Child Female 19 Dye 
Sibling Male 28 Smoking 
Bricklayer 
Proband Male 73 Smoking 
Electrician 
Child Male 62 Smoking 
Electrician 
Lynch[23] 1979 Proband Male 52 Organic chemist 
Father Male 68 Radiologist 
Proband Male 50 Smoking 
Wiring 
Sibling Male 24 Smoking 
Sibling Male 49 Smoking 
Mahboubi[24] 1981 Proband Female 66 None known 
Sibling Male 64 Smoking 
Farmer 
Child Male 50 Smoking 
Farmer 
Pilot 
Construction 
Egilsson[25] 1993 Proband Female 76 Farm 
Child Male 81 Smoking 
Farm 
Kenet[26] 1995 Proband Female 14 Cyclophosphamide 
Grandparent Male Unknown None known 
Ilíc[27] 2011 Proband Male 68 Smoking 
Farmer 
Parent Female 82 Farmer 
Spouse Female 63 Farmer 
Brown[28] 2014 Proband Male 76 Smoking 
Sibling Male 73 Smoking 
Sibling Female 60 Smoking 
Proband Male 60 None Known 
Child Female 76 None Known 
Child Male 50 None Known 
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Table 2. Cancer risks in Lynch syndrome by anatomic sites 
 
Anatomical site Cancer risk (%) 
Central nervous system 1-3 
Hepatobiliary 1.4-4 
Pancreas 1-6 
Colon 15-80 
Upper urinary tract 1-28 
Bladder 2-6 
Skin/sebaceous gland neoplasm 1-9 
Stomach 1-13 
Small bowel 3-6 
Ovary 1-24 
Endometrium 15-60 
Kidney 3.3 
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Table 3. Amsterdam II Criteria 
 
Amsterdam II Criteria 
 Three with histologically verified colorectal cancer, endometrial cancer, small bowel 
cancer, ureter cancer, or cancer of the renal pelvis. 
 Cancer involving two or more generations. 
 One or more cancer diagnoses in a family before 50 years of age. 
 
